Protein that drives liver damage could be a target for treatment

A severe form of fatty liver disease called nonalcoholic steatohepatitis (NASH) is the leading cause of liver transplantation, but there are few treatment options and currently no medications. In a new study, Yale researchers have identified a driver of liver damage that occurs in NASH and which may open new treatment options in the future.